Epigenetic Dysregulation-mediated COL12A1 Upregulation Predicts Worse Outcome in Intrahepatic Cholangiocarcinoma Patients

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2023 Jan 24

PMID 36694230

Authors

Zengwei Tang

Yuan Yang

Qi Zhang

Tingbo Liang

Affiliations

Soon will be listed here.

Abstract

Background: Collagen type XII alpha 1 chain (COL12A1) is associated with human cancer progression. Nevertheless, the expression pattern and the function of COL12A1 in intrahepatic cholangiocarcinoma (iCCA) remain unknown. The present study was performed to assess the role of COL12A1 in iCCA.

Results: A total of 1669 genes, differentially expressed between iCCA and nontumor liver tissue samples, were identified as potential tumor-specific biomarkers for iCCA patients. Of these, COL12A1 was significantly upregulated in clinical iCCA tissue samples and correlated with epithelial-mesenchymal transition gene set enrichment score and advanced tumor stage in clinical iCCA. COL12A1-high expression was associated with the poor prognoses of iCCA patients (n = 421) from four independent cohorts. Promoter hypermethylation-induced downregulation of miR-424-5p resulted in COL12A1 upregulation in clinical iCCA. Experimental knockout of COL12A1 inhibited the proliferation, invasiveness and growth of iCCA cells. MiR-424-5p had a therapeutic potential in iCCA via directly targeting COL12A1.

Conclusions: Promoter hypermethylation-induced miR-424-5p downregulation contributes to COL12A1 upregulation in iCCA. COL12A1 is a promising druggable target for epigenetic therapy of iCCA.

Citing Articles

Effects of DNA methylation and its application in inflammatory bowel disease (Review).

Akanyibah F, Zhu Y, Wan A, Ocansey D, Xia Y, Fang A Int J Mol Med. 2024; 53(6).

PMID: 38695222 PMC: 11093555. DOI: 10.3892/ijmm.2024.5379.

Comprehensive analysis of the clinical and biological significances for chemokine CXCL3 in cholangiocarcinoma.

Ren H, Yang X, Hou W, Meng J, Luo D, Zhang C Medicine (Baltimore). 2024; 103(11):e37460.

PMID: 38489741 PMC: 10939667. DOI: 10.1097/MD.0000000000037460.

Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches.

Khosla D, Misra S, Chu P, Guan P, Nada R, Gupta R Cancers (Basel). 2024; 16(4).

PMID: 38398194 PMC: 10887007. DOI: 10.3390/cancers16040801.

Integrating single-cell and bulk transcriptomic analyses to develop a cancer-associated fibroblast-derived biomarker for predicting prognosis and therapeutic response in breast cancer.

Li C, Yang L, Zhang Y, Hou Q, Wang S, Lu S Front Immunol. 2024; 14:1307588.

PMID: 38235137 PMC: 10791883. DOI: 10.3389/fimmu.2023.1307588.

ΔNp63α facilitates proliferation and migration, and modulates the chromatin landscape in intrahepatic cholangiocarcinoma cells.

Peng A, Lin X, Yang Q, Sun Y, Chen R, Liu B Cell Death Dis. 2023; 14(11):777.

PMID: 38012140 PMC: 10682000. DOI: 10.1038/s41419-023-06309-7.

References

Bridgewater J, Galle P, Khan S, Llovet J, Park J, Patel T . Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60(6):1268-89. DOI: 10.1016/j.jhep.2014.01.021. View

Tang Z, Yang Y, Zhang J, Fu W, Lin Y, Su G . Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma. J Cancer. 2019; 10(17):3985-3999. PMC: 6692627. DOI: 10.7150/jca.29354. View

Tang Z, Yang Y, Wang X, Meng W, Li X . Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma. BMJ Open. 2019; 9(1):e021693. PMC: 6352767. DOI: 10.1136/bmjopen-2018-021693. View

Sirica A, Gores G, Groopman J, Selaru F, Strazzabosco M, Wang X . Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. Hepatology. 2018; 69(4):1803-1815. PMC: 6433548. DOI: 10.1002/hep.30289. View

Banales J, Marin J, Lamarca A, Rodrigues P, Khan S, Roberts L . Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17(9):557-588. PMC: 7447603. DOI: 10.1038/s41575-020-0310-z. View

Farshidfar F, Zheng S, Gingras M, Newton Y, Shih J, Robertson A . Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep. 2017; 19(13):2878-2880. PMC: 6141445. DOI: 10.1016/j.celrep.2017.06.008. View

Jiao Y, Pawlik T, Anders R, Selaru F, Streppel M, Lucas D . Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45(12):1470-1473. PMC: 4013720. DOI: 10.1038/ng.2813. View

Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon S . Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell. 2017; 32(1):57-70.e3. PMC: 5524207. DOI: 10.1016/j.ccell.2017.05.009. View

Job S, Rapoud D, Dos Santos A, Gonzalez P, Desterke C, Pascal G . Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Hepatology. 2019; 72(3):965-981. PMC: 7589418. DOI: 10.1002/hep.31092. View

10.

Kelley R, Bridgewater J, Gores G, Zhu A . Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020; 72(2):353-363. DOI: 10.1016/j.jhep.2019.10.009. View

11.

Dong L, Lu D, Chen R, Lin Y, Zhu H, Zhang Z . Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell. 2021; 40(1):70-87.e15. DOI: 10.1016/j.ccell.2021.12.006. View

12.

Chen Q, Wang H, Li Z, Li F, Liang L, Zou Y . Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription. J Hepatol. 2021; 76(1):135-147. DOI: 10.1016/j.jhep.2021.08.027. View

13.

Zhang M, Yang H, Wan L, Wang Z, Wang H, Ge C . Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. 2020; 73(5):1118-1130. DOI: 10.1016/j.jhep.2020.05.039. View

14.

Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B . Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013; 144(4):829-40. PMC: 3624083. DOI: 10.1053/j.gastro.2013.01.001. View

15.

Chivu-Economescu M, Necula L, Matei L, Dragu D, Bleotu C, Sorop A . Collagen Family and Other Matrix Remodeling Proteins Identified by Bioinformatics Analysis as Hub Genes Involved in Gastric Cancer Progression and Prognosis. Int J Mol Sci. 2022; 23(6). PMC: 8950589. DOI: 10.3390/ijms23063214. View

16.

Mikula M, Rubel T, Karczmarski J, Goryca K, Dadlez M, Ostrowski J . Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct Integr Genomics. 2010; 11(2):215-24. DOI: 10.1007/s10142-010-0200-5. View

17.

Wu Y, Xu Y . Integrated bioinformatics analysis of expression and gene regulation network of COL12A1 in colorectal cancer. Cancer Med. 2020; 9(13):4743-4755. PMC: 7333847. DOI: 10.1002/cam4.2899. View

18.

Li Y, Su Z, Wei B, Qin M, Liang Z . Bioinformatics analysis identified MMP14 and COL12A1 as immune-related biomarkers associated with pancreatic adenocarcinoma prognosis. Math Biosci Eng. 2021; 18(5):5921-5942. DOI: 10.3934/mbe.2021296. View

19.

Dongre A, Weinberg R . New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018; 20(2):69-84. DOI: 10.1038/s41580-018-0080-4. View

20.

Guerra M, Florentino R, Franca A, Lima Filho A, Dos Santos M, Fonseca R . Expression of the type 3 InsP receptor is a final common event in the development of hepatocellular carcinoma. Gut. 2019; 68(9):1676-1687. PMC: 7087395. DOI: 10.1136/gutjnl-2018-317811. View